Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.2600 (2.94%) ($4.5100 - $5.5900) on Thu. Mar. 19, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.21% (three month average) | RSI | 22 | Latest Price | $5.2600(2.94%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -6.7% a day on average for past five trading days. | Weekly Trend | AUTL declines -19% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) DRIV(13%) EWI(12%) IBB(12%) BND(11%) BOTZ(11%) | Factors Impacting AUTL price | AUTL will decline at least -2.605% in a week (0% probabilities). VXX(-5%) VIXM(-5%) TLT(-2%) CEMB(-2%) USO(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.605% (StdDev 5.21%) | Hourly BBV | 0 () | Intraday Trend | 1.3% | | | |
|
1 - 5 Day Possible Target | $-28.78(-647.15%) | Resistance Level | $8.03 | 5 Day Moving Average | $5.61(-6.24%) | 10 Day Moving Average | $6.81(-22.76%) | 20 Day Moving Average | $8.03(-34.5%) | To recent high | -63.1% | To recent low | 2.9% | Market Cap | $N/A | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |